IL139478A0 - Hybrid protein - Google Patents

Hybrid protein

Info

Publication number
IL139478A0
IL139478A0 IL13947899A IL13947899A IL139478A0 IL 139478 A0 IL139478 A0 IL 139478A0 IL 13947899 A IL13947899 A IL 13947899A IL 13947899 A IL13947899 A IL 13947899A IL 139478 A0 IL139478 A0 IL 139478A0
Authority
IL
Israel
Prior art keywords
hybrid protein
mastocytes
basophils
protein
splits
Prior art date
Application number
IL13947899A
Other languages
English (en)
Original Assignee
Biotecon Ges Fur Biotechnologi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotecon Ges Fur Biotechnologi filed Critical Biotecon Ges Fur Biotechnologi
Publication of IL139478A0 publication Critical patent/IL139478A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Fire-Extinguishing Compositions (AREA)
IL13947899A 1998-05-13 1999-05-12 Hybrid protein IL139478A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19821285 1998-05-13
PCT/EP1999/003272 WO1999058571A2 (de) 1998-05-13 1999-05-12 Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung

Publications (1)

Publication Number Publication Date
IL139478A0 true IL139478A0 (en) 2001-11-25

Family

ID=7867540

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13947899A IL139478A0 (en) 1998-05-13 1999-05-12 Hybrid protein
IL139478A IL139478A (en) 1998-05-13 2000-11-05 Hybrid protein for inhibiting degeneration of mastocytes and its use

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL139478A IL139478A (en) 1998-05-13 2000-11-05 Hybrid protein for inhibiting degeneration of mastocytes and its use

Country Status (22)

Country Link
EP (1) EP1084146B1 (cs)
JP (1) JP4549533B2 (cs)
KR (1) KR100580541B1 (cs)
CN (1) CN1241945C (cs)
AT (1) ATE227739T1 (cs)
AU (1) AU755513B2 (cs)
BR (1) BR9910359A (cs)
CA (1) CA2331274C (cs)
CU (1) CU22997A3 (cs)
CZ (1) CZ294376B6 (cs)
DE (1) DE59903410D1 (cs)
DK (1) DK1084146T3 (cs)
ES (1) ES2187200T3 (cs)
HK (1) HK1036994A1 (cs)
HU (1) HUP0103601A3 (cs)
IL (2) IL139478A0 (cs)
MX (1) MXPA00011148A (cs)
NO (1) NO328361B1 (cs)
PL (1) PL201879B1 (cs)
PT (1) PT1084146E (cs)
RU (1) RU2214420C2 (cs)
WO (1) WO1999058571A2 (cs)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
US20040071736A1 (en) 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US20080038274A1 (en) 1999-09-23 2008-02-14 Foster Keith A Inhibition of secretion from non-neuronal cells
GB9922554D0 (en) * 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
IL153734A0 (en) * 2000-06-28 2003-07-06 Ira Sanders Methods for using tetanus toxin for beneficial purposes in animals (mammals)
GB0321344D0 (en) * 2003-09-11 2003-10-15 Health Prot Agency Re-targeted toxin conjugates
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
KR100845278B1 (ko) * 2006-08-04 2008-07-09 포항공과대학교 산학협력단 비만 세포의 활성을 유도하는 펩타이드 및 이를 포함하는면역조절제
EP2719392B1 (en) 2008-06-12 2019-07-24 Ipsen Bioinnovation Limited Fusion proteins for use in the treatment of acromegaly
ES2732205T3 (es) 2008-06-12 2019-11-21 Ipsen Bioinnovation Ltd Proteínas de fusión para uso en el tratamiento del cáncer
CA2731203C (en) * 2008-07-31 2017-01-03 Total S.A. Constructs and methods for the production and secretion of polypeptides
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
CN102241774B (zh) * 2010-05-27 2014-05-14 四川大学 重组IgE-Fc-抗EGFR单链抗体融合蛋白及其制备方法和用途
GB201108108D0 (en) 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
US20140056870A1 (en) 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
HUE053935T2 (hu) 2015-01-09 2021-08-30 Ipsen Bioinnovation Ltd Kationos neurotoxinok
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
GB201815817D0 (en) 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
GB201900621D0 (en) 2019-01-16 2019-03-06 Ipsen Biopharm Ltd Labelled polypeptides
GB201914034D0 (en) 2019-09-30 2019-11-13 Ipsen Biopharm Ltd Treatment of neurological disorders
GB202100566D0 (en) 2021-01-15 2021-03-03 Ipsen Biopharm Ltd Treatment of brain damage
GB202104294D0 (en) 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop
CA3213914A1 (en) 2021-03-30 2022-10-06 Mikhail KALINICHEV Treatment of pain & inflammatory disorders
CN117396217A (zh) 2021-03-30 2024-01-12 益普生生物制药有限公司 无催化活性的梭菌神经毒素用于疼痛和炎性疾病的治疗
GB202116795D0 (en) 2021-11-22 2022-01-05 Ipsen Biopharm Ltd Treatment of visceral pain
PL244930B1 (pl) 2021-12-08 2024-04-02 Gdanski Univ Medyczny Zastosowanie 2-metoksyestradiolu w leczeniu mastocytozy
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site
GB202214229D0 (en) 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9305735D0 (en) * 1993-03-19 1993-05-05 North John R Novel agent for controlling cell activity
IL116436A (en) * 1995-12-18 2006-12-31 Yissum Res Dev Co Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND

Also Published As

Publication number Publication date
PT1084146E (pt) 2003-02-28
IL139478A (en) 2008-06-05
NO328361B1 (no) 2010-02-01
NO20005637L (no) 2000-11-08
JP4549533B2 (ja) 2010-09-22
HUP0103601A3 (en) 2004-06-28
ES2187200T3 (es) 2003-05-16
CN1241945C (zh) 2006-02-15
AU755513B2 (en) 2002-12-12
EP1084146A2 (de) 2001-03-21
CZ294376B6 (cs) 2004-12-15
BR9910359A (pt) 2001-01-09
CA2331274A1 (en) 1999-11-18
HK1036994A1 (en) 2002-01-25
CN1300295A (zh) 2001-06-20
WO1999058571A2 (de) 1999-11-18
KR100580541B1 (ko) 2006-05-16
AU4260599A (en) 1999-11-29
HUP0103601A2 (hu) 2002-01-28
CZ20004161A3 (cs) 2001-04-11
DE59903410D1 (de) 2002-12-19
JP2002514659A (ja) 2002-05-21
PL201879B1 (pl) 2009-05-29
EP1084146B1 (de) 2002-11-13
MXPA00011148A (es) 2003-04-22
WO1999058571A3 (de) 2000-02-03
NO20005637D0 (no) 2000-11-08
RU2214420C2 (ru) 2003-10-20
KR20010042825A (ko) 2001-05-25
ATE227739T1 (de) 2002-11-15
PL344752A1 (en) 2001-11-19
DK1084146T3 (da) 2003-02-03
CA2331274C (en) 2010-04-06
CU22997A3 (es) 2004-10-12

Similar Documents

Publication Publication Date Title
IL139478A0 (en) Hybrid protein
EP0783527A4 (en) PROTEASE CATHEPSINE O2
EP1712623A3 (en) Selection of proteins using RNA-protein fusions
ES2145015T3 (es) Proteasas especificas de ubiquitina.
WO2000023564A3 (en) Protein design automation for protein libraries
ES2149149T1 (es) Proteinas de fijacion de interleuquina-18, su preparacion y utilizacion.
MY113489A (en) Reversible protease inhibitors
AU2002217010A1 (en) Peptides, the production and use thereof for binding immunoglobulins
IL145689A0 (en) Methods
EP0626450A3 (en) Fusion proteins containing the enzyme ubiquitin conjugate (E2).
FR2816410B1 (fr) Necessaire de detection de la proteine esm-1 et procede de detection mettant en oeuvre ledit necessaire
AU2001238212A1 (en) Modified fluorescent proteins
AU3186397A (en) Prion protein binding proteins and uses thereof
DE69634077D1 (de) Haemophilus adhäsionsproteinen
PT723552E (pt) Oligopeptidos derivados de fragmentos de proteina reactiva c
DE60023933D1 (en) Hybrid-toxine von bacillus thuringiensis
DK0942992T3 (da) O-fucosyltransferase
AU5178698A (en) Novel serine protease inhibitor nucleic acid molecules, proteins and uses hereof
DK1002056T3 (da) ppGpp-syntease og ekspressionssystem til forbedret fremstilling af protein af interesse
EP0846165A4 (en) NOVEL PROTEINS AND NUCLEIC ACID MOLECULES OF FILARIID NEMATODE CYSTEIN PROTEASE AND THEIR USE
BG102937A (en) Zona pelucida proteins as contraceptives
IL139272A0 (en) New peptide fragments for protein purification
WO1998030687A3 (de) Srcr domäne-enthaltendes protein
WO2003083099A3 (en) Purified polypeptides involved in protein synthesis and modification
SE9604439D0 (sv) New receptor

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
FF Patent granted